Document is current
Any future updates will be listed below
-
Authors
Brioli, Annamaria https://orcid.org/0000-0002-4072-7592
Lomaia, Elza https://orcid.org/0000-0003-3290-7961
Fabisch, Christian
Sacha, Tomasz https://orcid.org/0000-0002-7207-6595
Klamova, Hana
Morozova, Elena
Golos, Aleksandra
Ernst, Philipp https://orcid.org/0000-0001-5165-9874
Olsson-Stromberg, Ulla
Zackova, Daniela
Nicolini, Franck E.
Bao, Han
Castagnetti, Fausto https://orcid.org/0000-0002-0602-2628
Patkowska, Elzbieta https://orcid.org/0000-0001-8691-4310
Mayer, Jiri
Hirschbühl, Klaus https://orcid.org/0000-0002-4847-7460
Podgornik, Helena https://orcid.org/0000-0003-3752-2067
Paczkowska, Edyta https://orcid.org/0000-0001-7052-9741
Parry, Anne
Ernst, Thomas https://orcid.org/0000-0003-2147-489X
Voskanyan, Astghik
Szczepanek, Elzbieta
Saussele, Susanne https://orcid.org/0000-0003-0357-5785
Franke, Georg-Nikolaus https://orcid.org/0000-0001-8239-002X
Kiani, Alexander https://orcid.org/0000-0002-2494-4087
Faber, Edgar
Krause, Stefan https://orcid.org/0000-0002-5259-4651
Casado, Luis Felipe
Lewandowski, Krzysztof
Eder, Matthias
Anhut, Peter
Gil, Justyna
Südhoff, Thomas
Hebart, Holger https://orcid.org/0000-0003-4536-9955
Heibl, Sonja
Pfirrmann, Markus
Hochhaus, Andreas
Lauseker, Michael https://orcid.org/0000-0002-6662-7127
- License Information
-
More Information
Article History
Received: 14 September 2023
Revised: 15 February 2024
Accepted: 23 February 2024
First Online: 28 March 2024
Competing interests
: The registry received no support from pharmacological companies. The single authors have the following conflict of interest do declare: AB has participated in advisory boards from BMS, Janssen, GSK, Takeda and Sanofi and received honoraria and travel support from BMS, Janssen, GSK, Sanofi, Amgen, Gilead and Takeda; EL has received fees for lecturing and expert opinion from Novartis, Pfizer, Sotex, Pharmstandard and Fusion Pharma; HK supported lectures from Novartis and Angelini, travel support form Novartis; EM has received honoraria and travel support from Novartis, BMS and Pfizer; AG has participated in advisory boards from Roche and received honoraria and travel support form AMGEN, Novartis, Janssen, Pfizer; PE has received research support from Novartis and participated on advisory boards for Pfizer; DZ served as a member of advisory board for Novartis, served on a speakers bureau for Novartis, Pfizer and Angelini, as a consultant for Novartis and Angelini, and received travel support from Novartis, Pfizer, Angelini and Astra Zeneca; EPat has received consulting fees from KCR US, Inc., received honoraria from Amgen, Novartis, Servier, Angelini Pharma, Astellas Pharma and Pfizer and travel support from Amgen, Novartis, Servier, Angelini Pharma, Astellas Pharma, Pfizer, Jazz Pharma and BMS; KH has participated in advisory boards from Pfizer, Novartis, Incyte and GSK and received honoraria and travel support from Jazz, Novartis, Gilead, Roche, Pfizer, Amgen, Astellas Pharma, Merck and AbbVie; TE has received research support from Novartis, BMS, Incyte, Pfizer; GNF has participated in advisory boards from Novartis, received honoraria from BMS, Novartis, Gilead, Pfizer, Jazz Pharma, received travel support from Stemline, Gilead, Takeda and research support from Novartis; AK has participated in advisory boards and received honoraria and travel support from BMS/Celgene, Novartis and Pfizer; EF has received honoraria from Angelini, Novartis and Zentiva, is member of the Czech Advisory board for Novartis and has participated in advisory boards from Zentiva; LFC has participated in advisory boards from Novartis, BMS, Janssen, GSK, Astra Zeneca, Incyte, Beigene and Pfizer and received honoraria and travel support from BMS, Janssen, GSK, Astra Zeneca and Pfizer; KL has received honoraria for lectures, chairing sessions from Novartis, AbbVie, Angelini, Celgene, Pfizer, AOP Orphan and participated in advisory boards from Novartis, AbbVie, Angelini, Celgene, Pfizer, AOP Orphan; HH has participated in advisory boards and/or received travel support from BMS, Incyte, Novartis, Pfizer; SH has participated in advisory boards of Novartis, Celgene, BMS, AOP Orphan, AbbVie, and has received honoraria from Novartis, Celgene, BMS, AOP Orphan, AbbVie, Sanofi, Amgen; AH has received research support from Novartis, BMS, Incyte, Pfizer, Enliven and TERNS; ML has received research support from Novartis. All other authors declare no conflict of interest.
